Arvinas ARVN ARV-393 — Program-specific external expense

Similar metrics at other companies

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

RAPPRAP219Program External Expenses — Research And Development Expense

$15.82M+98.7%

ANROALTO-203 — Direct external program expenses:

$6K-99.2%

KYTXOther Program — External Research And Development Expenses Allocated By Program

$206K-63.1%

IDYAIDE397 — External Clinical Development Expenses

$3.52M-6.0%

CTMXCx904Egfrxcd3 — Total External Costs

$241K-78.3%

Questions, answered.

What is Arvinas's ARV-393 — program-specific external expense?

Arvinas (ARVN) reported ARV-393 — program-specific external expense of $3.7M in Q1 2026.

How has Arvinas's ARV-393 — program-specific external expense changed year-over-year?

Arvinas's ARV-393 — program-specific external expense increased by 42.3% year-over-year, from $2.6M to $3.7M.

What is the long-term trend for Arvinas's ARV-393 — program-specific external expense?

Over 2 years (2023 to 2025), Arvinas's ARV-393 — program-specific external expense has grown at a 181.6% compound annual growth rate (CAGR), from $1.4M to $11.1M.

What does ARV-393 — program-specific external expense mean?

This metric represents the direct, third-party costs incurred specifically for the development and advancement of a particular therapeutic program. It captures expenditures such as contract research organization fees, clinical trial site costs, and external manufacturing expenses associated with a single drug candidate. Monitoring this allows investors to assess the capital intensity and external resource allocation required to progress a specific asset through the pipeline.